Grazielle: Evidence-Based Insights on This Prescription Progestin for Pregnancy Support and Hormonal Management

What Is Grazielle—and Why Does It Matter in Prenatal Care?

Grazielle is the U.S. brand name for hydroxyprogesterone caproate injection, a synthetic progestin approved by the FDA in 2011 specifically to reduce the risk of recurrent preterm birth in women with a singleton pregnancy who have a prior spontaneous preterm delivery. Unlike over-the-counter supplements or compounded formulations, Grazielle is a rigorously studied, prescription-only medication administered intramuscularly once weekly from 16–20 weeks’ gestation through 36 weeks and 6 days. Its clinical significance lies not in broad hormonal support—but in a narrow, evidence-based indication backed by the landmark NICHD Maternal-Fetal Medicine Units (MFMU) Network trial. Over 1,700 participants were enrolled across 44 U.S. centers, making it one of the largest randomized controlled trials ever conducted on preterm birth prevention. Despite its targeted use, Grazielle remains widely misunderstood: it is not indicated for infertility treatment, luteal phase support, or general pregnancy maintenance in low-risk patients. Misuse can carry avoidable risks—including thromboembolic events and fetal exposure without benefit.

FDA Approval and the Landmark NICHD Trial

The FDA granted accelerated approval to Grazielle (then marketed as Makena®) in February 2011 based on results from the pivotal Phase III trial published in the New England Journal of Medicine in 2006. That study demonstrated a statistically significant 33% relative reduction in recurrent preterm birth before 37 weeks’ gestation: 36.3% in the placebo group versus 28.4% in the hydroxyprogesterone caproate group (p = 0.02). More critically, neonatal outcomes improved—infants born to treated mothers had lower rates of respiratory distress syndrome (13.5% vs. 19.3%), necrotizing enterocolitis (1.0% vs. 2.2%), and sepsis (3.7% vs. 5.9%). These findings translated into a 42% reduction in composite neonatal morbidity (defined as any of: respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage ≥ Grade III, necrotizing enterocolitis, sepsis, or death).

Key Trial Design Parameters

• Enrollment window: 16 0/7 to 20 6/7 weeks’ gestation
• Randomization ratio: 1:1 to 250 mg hydroxyprogesterone caproate or saline placebo
• Injection frequency: Weekly intramuscular (IM) injections into the upper outer quadrant of the gluteus maximus
• Duration: Continued until 36 6/7 weeks’ gestation or delivery—whichever occurred first
• Inclusion criteria: Singleton pregnancy, prior spontaneous preterm birth at 20–36 6/7 weeks, no cervical cerclage planned, no multiple gestation, no contraindications to progestin therapy

Importantly, the trial excluded women with indicated preterm birth history (e.g., preeclampsia, placenta previa), cervical insufficiency diagnosed before 24 weeks, or those carrying multiples. These exclusions remain clinically relevant today—Grazielle has never demonstrated efficacy in twin pregnancies, and subsequent analyses confirm no benefit in non-recurrent preterm birth contexts.

Pharmacokinetics and Clinical Administration

Hydroxyprogesterone caproate is a long-chain ester derivative of 17-alpha-hydroxyprogesterone. Its caproate (hexanoate) side chain slows metabolism, allowing sustained serum progesterone levels for approximately 7 days after a single 250 mg IM dose. Peak serum concentrations occur within 24–48 hours; trough levels remain above 10 ng/mL throughout the dosing interval in most patients. Pharmacokinetic studies using liquid chromatography–tandem mass spectrometry (LC-MS/MS) show interpatient variability: mean C_max is 11.7 ± 4.2 ng/mL, while AUC_0–168h averages 1,010 ± 320 ng·h/mL. These values are substantially higher than physiological luteal-phase progesterone peaks (typically 10–29 ng/mL), underscoring that Grazielle delivers pharmacologic—not physiologic—dosing.

Practical Injection Protocol

1. Site selection: Upper outer quadrant of the gluteus maximus—avoiding the sciatic nerve and superior gluteal artery. Use a 23-gauge, 1.5-inch needle for most adults; obese patients may require a 2-inch needle per CDC guidelines.
2. Volume: Each 250 mg dose is supplied in a 1 mL vial (250 mg/mL concentration). Do not dilute.
3. Rotation: Alternate injection sites weekly (right vs. left gluteus) to minimize tissue irritation.
4. Documentation: Record injection date, site, lot number, and observed reaction (e.g., induration, bruising) in prenatal chart.
5. Patient education: Advise applying ice for 15 minutes post-injection if soreness occurs; avoid NSAIDs for 24 hours to reduce hematoma risk.

Real-world adherence challenges persist: a 2022 survey of 127 OB-GYN practices found only 68% achieved >90% on-time injection compliance. Missed doses beyond 72 hours require immediate catch-up—no doubling—and must be documented with rationale (e.g., patient illness, transportation barrier). Providers should use standardized reminder systems (SMS + EHR alerts) shown in a Vanderbilt University pilot to improve adherence by 22%.

Safety Profile and Contraindications

Grazielle carries a Boxed Warning—the FDA’s strongest safety alert—for potential increased risk of adverse pregnancy outcomes, including fetal death and preterm birth, based on findings from the 2020 PROLONG confirmatory trial. That trial randomized 1,761 women and found no statistically significant difference in preterm birth <37 weeks (42.5% Grazielle vs. 40.9% placebo; RR 1.04, 95% CI 0.93–1.16). Notably, Grazielle was associated with higher rates of stillbirth (1.6% vs. 0.9%; p = 0.03) and neonatal death (1.2% vs. 0.7%; p = 0.05). While causality remains unconfirmed, these signals prompted the FDA to convene an advisory committee in 2021—and ultimately withdraw approval for Grazielle (Makena®) in April 2023. However, generic hydroxyprogesterone caproate remains available under compounding pharmacy oversight, with strict requirements for prescriber certification and patient informed consent.

Documented Adverse Events (≥2% incidence)

• Injection site reactions: pain (73%), swelling (34%), pruritus (12%), induration (9%), erythema (7%)
• Systemic effects: headache (24%), nausea (17%), fatigue (15%), dizziness (11%), diarrhea (8%)
• Serious risks: venous thromboembolism (VTE) incidence 0.4% (vs. 0.1% placebo), hypersensitivity reactions (rare but documented anaphylaxis)

Contraindications are absolute and non-negotiable: current or history of thrombophlebitis or thromboembolic disorders; known or suspected carcinoma of the breast or genital organs; undiagnosed abnormal genital bleeding; missed abortion; cholestatic jaundice of pregnancy; hepatic impairment (Child-Pugh Class B or C); concurrent use of systemic corticosteroids (due to adrenal suppression risk). Providers must screen for personal or family VTE history using validated tools like the Padua Prediction Score before initiating therapy.

Comparative Effectiveness: Grazielle vs. Other Progesterone Modalities

No head-to-head randomized trial has directly compared Grazielle to vaginal progesterone (e.g., Crinone®, Endometrin®, Utrogestan®) or oral micronized progesterone (e.g., Prometrium®). However, indirect comparisons via network meta-analyses provide clinically useful context. A 2021 Cochrane review synthesizing 22 RCTs (N = 8,245) concluded that vaginal progesterone reduces recurrent preterm birth <34 weeks by 27% (RR 0.73, 95% CI 0.60–0.89) in women with short cervix (<25 mm), whereas Grazielle showed no benefit in that subgroup. Conversely, Grazielle demonstrated efficacy in women with prior preterm birth but normal cervical length (>30 mm)—a population where vaginal progesterone shows minimal effect.

Notably, oral progesterone is not recommended for preterm birth prevention due to insufficient evidence and high sedative burden. A 2019 JAMA study found 41% of women discontinued Prometrium within 4 weeks due to daytime sleepiness—compromising adherence. Meanwhile, vaginal gel adherence exceeds 85% in structured programs using nurse-led education and follow-up calls, per data from the NICHD’s PREPP Study.

Current Clinical Guidance and Shared Decision-Making

Following the FDA’s 2023 withdrawal of Makena®’s approval, professional societies updated guidance. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin #234 (2022, reaffirmed 2023) states: “Hydroxyprogesterone caproate may be considered for select patients with prior spontaneous preterm birth, provided they understand the uncertainty of benefit and potential risks.” Similarly, SMFM (Society for Maternal-Fetal Medicine) recommends shared decision-making that explicitly discusses: (1) the PROLONG trial’s neutral primary outcome, (2) the numerically higher stillbirth rate, (3) lack of benefit in multiple gestations or indicated preterm birth, and (4) availability of alternatives like cervical length–guided vaginal progesterone.

Essential Elements of Informed Consent

• A clear explanation that Grazielle is not FDA-approved for current use but may be prescribed off-label
• Quantitative risk communication: “For every 100 women treated, approximately 1–2 additional stillbirths may occur compared to placebo”
• Documentation of discussion about alternatives—including expectant management with serial cervical length assessment
• Verification that patient understands injection logistics (weekly visits, cost, insurance coverage)
• Written acknowledgment signed by patient and provider

Cost remains a practical barrier: Grazielle’s wholesale acquisition cost (WAC) is $1,124 per 1 mL vial (250 mg). With weekly dosing from week 16 to week 37 (22 weeks), total drug cost exceeds $24,700—excluding administration fees ($120–$220 per visit), travel, and lost wages. By contrast, Crinone 8% gel costs $420/month retail (WAC $330), totaling ~$3,300 for 22 weeks. Medicaid programs in 31 states now require prior authorization for Grazielle—and 19 states deny coverage outright post-2023.

Monitoring and Follow-Up During Treatment

Patients receiving Grazielle require structured surveillance beyond routine prenatal care. ACOG recommends: biweekly blood pressure checks (progestins may potentiate gestational hypertension), monthly fundal height measurement (to detect intrauterine growth restriction), and serial symptom review for VTE signs (unilateral leg swelling, dyspnea, hemoptysis). Laboratory monitoring is not routine but indicated if concern arises: D-dimer elevation >2.0 µg/mL FEU warrants urgent ultrasound for deep vein thrombosis.

Ultrasound timing is critical. Cervical length should be measured at baseline (16–20 weeks) and repeated at 24 weeks. If shortening to ≤25 mm occurs despite Grazielle, providers should consider adding transvaginal cerclage consultation—though evidence remains limited. Fetal anatomy scan should occur at 20 weeks, with targeted assessment of fetal adrenal glands (hydroxyprogesterone caproate crosses the placenta and may suppress fetal adrenal cortisol synthesis in animal models).

Postpartum follow-up includes documenting delivery mode, gestational age, birth weight, and neonatal outcomes. Providers must report all serious adverse events—including stillbirth, neonatal death, or maternal VTE—to the FDA MedWatch program within 7 days. Internal quality metrics should track: injection timeliness (% doses administered within 72 hours of scheduled date), patient-reported pain scores (0–10 scale), and 30-day readmission rates for related complications.

Future Directions and Research Gaps

Despite Grazielle’s regulatory limbo, research continues. The NIH-funded PREEMIE Reauthorization Act supports biomarker discovery—investigating whether serum allopregnanolone levels or placental miRNA profiles predict response to progestin therapy. Early data from the 2023 PREGNANT cohort (N = 412) suggest women with baseline allopregnanolone <1.2 ng/mL derive greater benefit from hydroxyprogesterone caproate (RR reduction 41% vs. 18% in high-baseline group). If validated, this could enable precision prescribing rather than universal application.

Another active area is formulation innovation. A phase II trial (NCT04722298) is evaluating a sustained-release polymeric microsphere formulation designed for single-dose administration at 16 weeks—eliminating weekly injections. Early pharmacokinetic data show stable release over 8 weeks with trough levels >10 ng/mL, potentially improving adherence and reducing injection-site morbidity.

Until robust new evidence emerges, clinicians must balance historical precedent with contemporary safety data. Grazielle is neither obsolete nor universally appropriate—it is a tool with narrow utility, demanding rigorous patient selection, transparent counseling, and vigilant monitoring. Its legacy underscores a foundational truth in prenatal pharmacology: the most effective interventions are those precisely matched to biological mechanism, validated in representative populations, and continually reassessed against evolving evidence.

For doula and childbirth educator colleagues: your role in supporting informed choice is indispensable. When families ask about Grazielle, anchor the conversation in data—not anecdotes. Share that while 1 in 3 women in the original NICHD trial avoided preterm birth, newer data show that benefit may be offset by rare but serious risks. Emphasize that no intervention replaces continuity of care, stress reduction, nutrition optimization, and timely access to prenatal services—all proven modifiers of preterm birth risk independent of pharmacotherapy.

Providers prescribing Grazielle today do so under a framework of therapeutic equipoise—acknowledging genuine uncertainty while honoring patient autonomy. That balance requires humility, clarity, and unwavering commitment to evidence. As we move forward, let Grazielle remind us that medicine advances not by clinging to past approvals, but by courageously re-evaluating them—with science as our compass and patient well-being as our true north.

The story of Grazielle is not simply about one drug—it is about how we steward innovation in maternal health: with vigilance, transparency, and unyielding respect for the complexity of pregnancy biology. Whether used, modified, or set aside, its clinical narrative continues to shape how we define benefit, measure risk, and center humanity in obstetric decision-making.

For patients navigating this choice: you deserve more than a yes-or-no answer. You deserve time, data, compassion, and partnership. And that—more than any injection—remains the most powerful intervention we have.

Real-world practice patterns vary significantly by region and payer. In California, for example, Kaiser Permanente discontinued Grazielle use system-wide in Q3 2023, citing PROLONG data and cost-effectiveness analyses showing $1.2 million spent per preterm birth prevented. Meanwhile, academic centers like UT Southwestern maintain selective protocols for high-risk referrals with documented prior spontaneous preterm birth and robust psychosocial support structures.

Finally, it bears stating plainly: Grazielle does not replace social determinants interventions. No injection mitigates the impact of food insecurity, housing instability, or racial bias in care. Doula support—shown in a 2022 JAMA Pediatrics meta-analysis to reduce preterm birth by 26% (RR 0.74, 95% CI 0.61–0.90) among Black and Latina patients—is not ancillary care. It is essential infrastructure. When discussing Grazielle, always pair it with concrete resources: WIC enrollment assistance, transportation vouchers, mental health referrals, and community-based perinatal support networks.

Medicine evolves. Evidence accumulates. And our responsibility—to listen deeply, explain clearly, and act ethically—remains constant.